Jefferies reiterates ‘Buy' on Sanofi (SAN), sets €100 price target
Jefferies reiterated its "Buy" recommendation on French pharmaceutical giant Sanofi, setting a price target of €100. This analyst endorsement propelled the company's stock, which is trading up 3.1% at €75.79 on Euronext Paris as of 4 June 2026. The previous session saw the shares close at €73.52.
The positive momentum also stems from several strategic initiatives announced by Sanofi. The firm launched "Action 2026," a global employee share ownership plan offering stock at a preferential price of €59.87, designed to enhance employee capital involvement. Concurrently, Sanofi detailed a collaboration with Biogen aimed at accelerating rare disease diagnosis in France, alongside a partnership with Snowflake to optimise drug development through artificial intelligence.
These developments underscore Sanofi's strategic focus on innovation and employee engagement. The Parisian market has reacted favourably to these announcements, positioning Sanofi as a dynamic entity within the European pharmaceutical sector.
Why Jefferies' Reaffirmation Boosted Sanofi's Shares
Sanofi is a major French pharmaceutical company, focused on the research, development, manufacture, and marketing of essential medicines and vaccines. Its business model revolves around selling these innovative products to healthcare systems and patients worldwide, which is how it generates its revenue.
The primary driver behind Sanofi's share price increase today is the reaffirmation of a "Buy" recommendation by financial institution Jefferies, coupled with an ambitious price target of €100. This decision comes from analysts who, after a deep dive into the company's fundamentals, growth prospects, and strategic market positioning, believe that Sanofi's current share price does not reflect its true value. This positive re-evaluation, which arrives as Sanofi advances strategic initiatives like its "Action 2026" employee share plan and innovative partnerships with Biogen and Snowflake, signals significant upside potential to investors.
This renewed confidence from a prominent financial institution has had an immediate impact on market perception. Sanofi's shares are currently trading at €75.79, marking a 3.1% rise from yesterday's closing price of €73.52.
Imagine a highly respected art appraiser who, after a thorough examination of a painting, significantly revises its estimated future value upwards. This new, higher valuation, based on newly appreciated artistic merit and market potential, instantly draws the attention of collectors and investors, validating the artwork's quality and future worth.
Sanofi
Sanofi (SAN) is a global pharmaceutical company focused on developing, manufacturing, and marketing a diverse range of therapeutic solutions across the United States, Europe, and other international markets. Its operations are structured into three key segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals division offers specialised treatments, including monoclonal antibodies, therapies for multiple sclerosis, neurological conditions, inflammatory and rare diseases, oncology, and rare blood disorders, alongside diabetes medications and established cardiovascular products. The Vaccines segment provides immunisations for poliomyelitis, pertussis, influenza, and meningitis, among others. Its Consumer Healthcare portfolio encompasses products for allergies, coughs and colds, pain relief, digestive health, and various wellness and skincare items. Sanofi also maintains a pipeline of pharmaceutical products and vaccines under development, including collaborations with GlaxoSmithKline for a COVID-19 vaccine and Stanford University School of Medicine for immunology research. Founded in 1973, Sanofi is headquartered in Paris, France.